Viatris Inc.’s Stock Price Plummets to $9.53, Marking a Steep 15.21% Drop

Viatris Inc. (VTRS)

9.53 USD -1.71 (-15.21%) Volume: 47.46M

Viatris Inc.’s stock price is currently at 9.53 USD, experiencing a sharp decline of -15.21% this trading session, with a high trading volume of 47.46M. The stock has seen a significant downtrend YTD with a percentage change of -24.22%, reflecting the company’s challenging market performance.

Latest developments on Viatris Inc.

Viatris reported its fourth-quarter and full-year 2024 financial results, along with its 2025 financial guidance, which led to a slide in its stock price after missing Q4 2024 estimates. The company also announced the maintenance of its dividend policy for 2025 and quarterly dividend. Additionally, Viatris launched a global review and plans aggressive share buybacks. Despite facing challenges like the FDA warning and import curbs on its India plant, Viatris continues to navigate through financial struggles, with its stock price tumbling due to missed revenue estimates and lower 2025 guidance.

Viatris Inc. on Smartkarma

Analysts on Smartkarma, such as Baptista Research, are closely following Viatris Inc. and its recent performance. In a report titled “Viatris Inc.: Expansion of Innovative Portfolio As A Vital Factor Driving Growth! – Major Drivers,” Baptista Research highlights the key elements impacting Viatris‘s financial position. The company’s Q3 2024 results showed significant revenue growth, reaching $3.8 billion, a 3% increase on an operational basis. Moreover, Viatris achieved its sixth consecutive quarter of growth in adjusted EBITDA and adjusted earnings per share (EPS).

For more insights on Viatris and other companies, independent analysts like those at Baptista Research provide valuable analysis on Smartkarma. By delving into the details of Viatris‘s performance, analysts offer a comprehensive view of the company’s strengths and challenges. Investors can leverage this research to make informed decisions about their investment strategies and stay updated on the latest developments in the market.

A look at Viatris Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Looking at the Smartkarma Smart Scores for Viatris, the company seems to have a positive long-term outlook. With high scores in Value and Dividend, investors may find Viatris to be a solid investment option. Additionally, a strong score in Growth indicates potential for future expansion and profitability. However, the lower scores in Resilience suggest that the company may face some challenges in terms of weathering economic downturns. Overall, Viatris‘ Momentum score of 4 shows that the company is moving in the right direction and gaining traction in the market.

Viatris Inc. is a pharmaceutical company that focuses on producing medicines for a wide range of therapeutic areas, including both noncommunicable and infectious diseases. With a global client base, Viatris is positioned to reach patients around the world. The company’s high scores in Value and Dividend reflect its strong financial standing and commitment to returning value to shareholders. While there may be some resilience challenges, Viatris‘ Growth and Momentum scores suggest that it has the potential for continued success in the pharmaceutical industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma